Revenue
2023
2024
Contineum Therapeutics, Inc. (CTNM)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | — | $0 | $50.0M |
| Research & development | $51.5M | $38.4M | $27.6M |
| Operating expenses | $68.1M | $50.9M | $33.9M |
| Operating income | −$68.1M | −$50.9M | $16.1M |
| EBITDAderived | −$67.7M | −$50.6M | $16.3M |
| Net income | −$60.0M | −$42.3M | $22.7M |
| Basic EPSper diluted share | -$2.17 | -$2.18 | $1.36 |
| Diluted EPSper diluted share | -$2.17 | -$2.18 | $0.08 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 · 10b5-1 | Lorrain Daniel S.Chief Scientific Officer | SellClass A Common Stock | 4.2K | $13.16 | $54.9K | 139.4K |
| May 1, 2026Form 4 · 10b5-1 | Lorrain Daniel S.Chief Scientific Officer | SellClass A Common Stock | 300 | $13.84 | $4.2K | 143.5K |
| May 1, 2026Form 4 · 10b5-1 | Lorrain Daniel S.Chief Scientific Officer | SellClass A Common Stock | 3.9K | $13.06 | $50.5K | 143.8K |
| Apr 6, 2026Form 4 · 10b5-1 | Lorrain Daniel S.Chief Scientific Officer | SellClass A Common Stock | 4.2K | $13.43 | $56.0K | 147.7K |
| Mar 2, 2026Form 4 · 10b5-1 | Lorrain Daniel S.Chief Scientific Officer | SellClass A Common Stock | 4.2K | $15.01 | $62.6K | 151.9K |